Immuneering Co. (NASDAQ:IMRX - Get Free Report) has been given a consensus recommendation of "Hold" by the eight ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $12.80.
IMRX has been the subject of several research reports. Needham & Company LLC reissued a "buy" rating and set a $15.00 price objective on shares of Immuneering in a research report on Tuesday. Chardan Capital reissued a "buy" rating and issued a $13.00 price target on shares of Immuneering in a research note on Wednesday. Finally, Morgan Stanley lowered Immuneering from an "equal weight" rating to an "underweight" rating in a report on Friday, December 13th.
Check Out Our Latest Analysis on IMRX
Institutional Trading of Immuneering
A number of hedge funds and other institutional investors have recently modified their holdings of IMRX. Acadian Asset Management LLC acquired a new position in Immuneering during the second quarter worth $67,000. Renaissance Technologies LLC bought a new position in shares of Immuneering in the 2nd quarter valued at about $447,000. XTX Topco Ltd increased its stake in shares of Immuneering by 37.3% during the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company's stock worth $44,000 after purchasing an additional 9,274 shares during the last quarter. Marshall Wace LLP bought a new stake in Immuneering in the second quarter valued at approximately $492,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Immuneering in the 2nd quarter valued at $44,000. Institutional investors and hedge funds own 67.65% of the company's stock.
Immuneering Stock Performance
IMRX stock traded down $0.36 during mid-day trading on Thursday, hitting $2.00. 4,851,376 shares of the company were exchanged, compared to its average volume of 17,431,006. Immuneering has a 1-year low of $1.00 and a 1-year high of $7.68. The firm's 50 day simple moving average is $2.04 and its 200 day simple moving average is $1.77. The firm has a market cap of $62.10 million, a P/E ratio of -1.02 and a beta of -0.34.
About Immuneering
(
Get Free ReportImmuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Further Reading
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
